Biotech Values

[mcbio]

SRPT (acquire another DMD drug?) -

Would be curious if this positive news opens SRPT to working with another DMD player to expand their pipeline or if they will just remain focused on their own internal pipeline.

BTW, I recalled a prior article from last year that talked about SRPT wanting to acquire other DMD drugs to complement their own pipeline. Here it is: http://www.biospace.com/News/sarepta-and-biomarin-rivalry-heats-up-as-sarepta/384281.

Relevant quote from that article:

If Sarepta does acquire another drug for DMD, the strategy would be to potentially mix the new drug with eteplirsen for a cocktail of treatments. In a recent interview with Bloomberg Business, Kay said, “We are going to own DMD,” adding that the company hoped to offer “a menu of options” to patients.

So, now that SRPT would appear to be in a much better position to acquire another DMD drug, I'm curious what they have in mind.